DT-Web

DB01378 - Magnesium


Identification
Name Magnesium
Accession Number DB01378
Type small molecule
Description Magnesium hydroxide is used primarily in "Milk of Magnesia", a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn. When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in evacuation of colonic contents.
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 24.305
Groups experimental
Monoisotopic Weight 23.985041898
Pharmacology
Indication Not Available
Mechanism of action Not Available
Absorption Not Available
Protein binding Not Available
Biotransformation Not Available
Route of elimination Not Available
Toxicity Not Available
Affected organisms Not Available
Interactions
Drug Interactions
Drug Mechanism of interaction
Alendronate Formation of non-absorbable complexes
Amprenavir The antiacid decreases the absorption of amprenavir
Atazanavir This gastric pH modifier decreases the levels/effects of atazanavir
Chloroquine The antiacid decreases the absorption of chloroquine
Ciprofloxacin Formation of non-absorbable complexes
Clodronate Formation of non-absorbable complexes
Dapsone Formation of non-absorbable complexes
Deferiprone Deferiprone serum concentrations may be decreased by magnesium salts.
Delavirdine Magnesium antacids may decrease the absorption of delavirdine.
Demeclocycline Formation of non-absorbable complexes
Dihydroquinidine barbiturate The antiacid decreases the absorption of quinidine
Doxycycline Formation of non-absorbable complexes
Enoxacin Formation of non-absorbable complexes
Etidronic acid Formation of non-absorbable complexes
Fosamprenavir The antiacid decreases the absorption of amprenavir
Gatifloxacin Formation of non-absorbable complexes
Gemifloxacin Formation of non-absorbable complexes
Grepafloxacin Magnesium may decrease the absorption of grepafloxacin. Doses should be spaced apart by at least 2 hours.
Ibandronate Formation of non-absorbable complexes
Indinavir Magnesium may decrease the absorption of indinavir.
Levofloxacin Formation of non-absorbable complexes
Lomefloxacin Formation of non-absorbable complexes
Methacycline Formation of non-absorbable complexes
Minocycline Formation of non-absorbable complexes
Moxifloxacin Formation of non-absorbable complexes
Norfloxacin Formation of non-absorbable complexes
Ofloxacin Formation of non-absorbable complexes
Oxytetracycline Formation of non-absorbable complexes
Pefloxacin Formation of non-absorbable complexes
Polystyrene sulfonate Risk of alkalosis in renal impairment
Quinidine Magnesium antacids may decrease the absorption of quindine.
Quinidine barbiturate The antiacid decreases the absorption of quinidine
Risedronate Formation of non-absorbable complexes
Rosuvastatin Magnesium-containing antacids may decrease the absorption of rosuvastatin.
Temafloxacin Formation of non-absorbable complexes
Tetracycline Formation of non-absorbable complexes
Trovafloxacin Formation of non-absorbable complexes
Food Interactions Not Available

Targets


Sodium/potassium-transporting ATPase alpha-1 chain
Name Sodium/potassium-transporting ATPase alpha-1 chain
Gene Name ATP1A1
Pharmacological action unknown
Actions Not Available
References
  • Buchachenko AL, Kuznetsov DA, Berdinskii VL: [New mechanisms of biological effects of electromagnetic fields] Biofizika. 2006 May-Jun;51(3):545-52. - Pubmed
  • Sirijovski N, Olsson U, Lundqvist J, Al-Karadaghi S, Willows RD, Hansson M: ATPase activity associated with the magnesium chelatase H-subunit of the chlorophyll biosynthetic pathway is an artefact. Biochem J. 2006 Dec 15;400(3):477-84. - Pubmed
  • Balasubramaniyan V, Nalini N: Leptin alters brain adenosine triphosphatase activity in ethanol-mediated neurotoxicity in mice. Singapore Med J. 2006 Oct;47(10):864-8. - Pubmed
  • Nogovitsina OR, Levitina EV: Neurological aspects of the clinical features, pathophysiology, and corrections of impairments in attention deficit hyperactivity disorder. Neurosci Behav Physiol. 2007 Mar;37(3):199-202. - Pubmed
DTHybrid score 0.7588

Predictions


Id Partner name Gene Name Score
566 Serotransferrin TF 0.0538
558 Solute carrier family 12 member 1 SLC12A1 0.0385
295 Carbonic anhydrase 1 CA1 0.0298
6150 Solute carrier organic anion transporter family member 4C1 SLCO4C1 0.028
357 Carbonic anhydrase 2 CA2 0.0223
610 Calcium-activated potassium channel subunit alpha 1 KCNMA1 0.0221
592 Carbonic anhydrase 4 CA4 0.0214
6139 Solute carrier organic anion transporter family member 1A2 SLCO1A2 0.0187
3932 Glutathione S-transferase A2 GSTA2 0.017
587 Serum albumin ALB 0.0164
6017 Cholesterol side-chain cleavage enzyme, mitochondrial CYP11A1 0.0156
1405 Thiopurine S-methyltransferase TPMT 0.0148
6158 Solute carrier organic anion transporter family member 1C1 SLCO1C1 0.0143
466 Solute carrier family 12 member 3 SLC12A3 0.0124
6157 Solute carrier organic anion transporter family member 1B3 SLCO1B3 0.0124
781 ATP-sensitive inward rectifier potassium channel 11 KCNJ11 0.0123
1588 Multidrug resistance protein 1 ABCB1 0.0123
3426 Glutamine synthetase glnA 0.0121
3987 Glutamine synthetase GLUL 0.0121
4205 Carbonic anhydrase 9 CA9 0.0118
3007 Carbonic anhydrase 12 CA12 0.0118
1490 Solute carrier organic anion transporter family member 1B1 SLCO1B1 0.0108
741 Potassium voltage-gated channel subfamily KQT member 1 KCNQ1 0.0103
6142 Solute carrier family 22 member 8 SLC22A8 0.0102
1729 Solute carrier family 22 member 6 SLC22A6 0.0098
6047 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A PDE1A 0.0093
5692 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B PDE1B 0.0087
392 Voltage-dependent P/Q-type calcium channel subunit alpha-1A CACNA1A 0.0087
1561 Troponin C, slow skeletal and cardiac muscles TNNC1 0.0081
4160 Voltage-dependent calcium channel subunit alpha-2/delta-2 CACNA2D2 0.008
4512 Cytochrome P450 3A4 CYP3A4 0.0076
964 Voltage-dependent T-type calcium channel subunit alpha-1H CACNA1H 0.0073
6167 Organic solute transporter subunit beta OSTB 0.0066
6166 Organic solute transporter subunit alpha OSTA 0.0066
6024 Cytochrome P450 1A1 CYP1A1 0.0065
465 Calmodulin CALM1 0.0062
6153 Solute carrier organic anion transporter family member 4A1 SLCO4A1 0.0054
1632 Solute carrier organic anion transporter family member 2B1 SLCO2B1 0.0042
776 Bile salt export pump ABCB11 0.0041
4119 Cytochrome P450 2D6 CYP2D6 0.0037
↑